Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

MEVPRO-2 (NCT06629779) is a global, randomized, double-blind, placebo‑controlled phase III trial in ARPI-naïve mCRPC patients. The key inclusion and exclusion criteria are detailed in the table below.

The PSA progression free survival in Arm A was 2.6 months versus 2.5 months in Arm B, and radiologic progression free survival was 2.1 months and 1.9 months in arm A and B, respectively. The median ...

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

A dual-target CAR T-cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T-cell ...

The empirical dietary inflammatory pattern (EDIP) score, used in the study to measure the inflammatory potential of patients' ...

The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test ...

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting ...

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

A dietitian has shared the exact reason some endometriosis symptoms are getting worse and what you can do to help ease them.

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...